IRLAB receives acceptance for two abstracts at AD/PD™ 2026: The 20th International Conference on Alzheimer’s and Parkinson’s Diseases

Gothenburg, Sweden, November 7, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that two abstracts have been accepted for presentation at the international conference AD/PD 2026, to be held in Copenhagen on March 17–21.

IRLAB publishes interim report for the period January – September 2025

IRLAB: Invitation to the interim report for Q3 2025 presentation and webcast